The Helicobacter pylori Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Helicobacter pylori Infections. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Helicobacter pylori Infections and features dormant and discontinued products.

GlobalData tracks 29 drugs in development for Helicobacter pylori Infections by 27 companies/universities/institutes. The top development phase for Helicobacter pylori Infections is preclinical with 13 drugs in that stage. The Helicobacter pylori Infections pipeline has 23 drugs in development by companies and six by universities/ institutes. Some of the companies in the Helicobacter pylori Infections pipeline products market are: Crestone, ImevaX and TenNor Therapeutics.

The key targets in the Helicobacter pylori Infections pipeline products market include Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K(+) ATPase Subunit Alpha or Proton Pump or ATP4A or EC 7.2.2.19), RNA Polymerase (EC 2.7.7.6), and Multidrug Efflux Pump Subunit AcrB (AcrAB Tolc Multidrug Efflux Pump Subunit AcrB or Acridine Resistance Protein B or acrB).

The key mechanisms of action in the Helicobacter pylori Infections pipeline product include Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K(+) ATPase Subunit Alpha or Proton Pump or ATP4A or EC 7.2.2.19) Inhibitor with three drugs in Pre-Registration. The Helicobacter pylori Infections pipeline products include four routes of administration with the top ROA being Oral and nine key molecule types in the Helicobacter pylori Infections pipeline products market including Small Molecule, and Subunit Vaccine.

Helicobacter pylori Infections overview

Helicobacter pylori (H. pylori) infection occurs when the Helicobacter pylori (H. pylori) bacteria infect the stomach, typically during childhood. A leading cause of stomach ulcers, this infection is asymptomatic for many, with over half of the global population potentially affected. Recognition often arises when peptic ulcer symptoms manifest, prompting healthcare providers to test for H. pylori. Peptic ulcers, affecting the stomach (gastric ulcer) or the initial part of the small intestine (duodenal ulcer), are indicative of H. pylori involvement. Antibiotics form the primary treatment for H. pylori infection, emphasizing the importance of diagnosis and intervention in managing peptic ulcer complications.

For a complete picture of Helicobacter pylori Infections’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.